Summary
The nano-magnetic ferrofluid was prepared by chemical coprecipitation and its acute toxicology was investigated. The effective diameter (Eff. Diam.) of the magnetic particles was about 19.9 nm, and the concentration of the ferrofluid was 17.54 mg/ml. The acute toxic reaction and the main viscera pathological morphology of mice were evaluated after oral, intravenous and intraperitoneal administration of the nano-magnetic ferrofluid of different doses respectively. Half lethal dose (LD50)>2104.8 mg/kg, maximum non-effect dose (ED0)=320.10mg/kg with oral; LD50>438.50 mg/kg, ED0=160.05 mg/kg with intravenous route; and LD50>1578.6 mg/kg, ED0=320.10 mg/kg with intraperitoneal administration. Degeneration and necrosis of viscera were not found. So the nano-magnetic ferrofluid, of which toxicity is very low, may be used as a drug carrier.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Raj K, Moskowitz R. Commerical applications of ferrofluids. J Magn Magn Mater, 1990, 85:233
Hisae I, Kota O, Miki Aet al. Detection of tumor cells in blood using CD45 magnetic cell separation followed by nested mutant allele-specific amplification of p53 and K-ras genes in patients with colorectal cancer. Int J Cancer, 2000, 89(4): 337
Frija G, Clement O, de Kerviler E. Overview of contrast enhancement with iron oxides. Invest Radiol, 1994, 29(Suppl 2):s75
Goodwin S C, Bittner C A, Peterson C Let al. Single-dose toxicity study of hepatic intra-arterial infusion of doxorubicin coupled to a novel magnetically targeted drug carrier. Toxicol Sci, 2001, 60(1):177
Jordan A, Scholz R, Wust Pet al. Effects of magnetic fluid hyperthermia (MFH) on C3H mammary carcinoma in vivo. Int J Hyperthermia, 1997, 13(6):587
Lubbe A S, Bergemann C, Riess Het al. Clinical experiences with magnetic drug targeting: a phase I study with 4′-epidoxorubicin in 14 patients with advanced solid tumors. Cancer Res, 1996, 56(20):4686
Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev, 2003, 55(3):329
Yudelson, Joseph S. Preparation and magnetic properties of very small magnetite-dextran particles. United States Patent, 5349957
SFDA. Good Laboratory Practice 2003 (Chinese). Chinese State Food and Drug Administration. 2003. 8
Guidance for industry: single dose acute toxicity testing for pharmaceutical. CEDR, 1996.
Toxicokinetics: the assessment of systemic exposure in toxicity studies. CEDR, 1995.
Hafeli U O, Pauer G J. In vitro and in vivo toxicity of magnetic microspheres. J Magn Magn Mater, 1999, 94:76
Wagner S, Schnorr J, Pilgrimm Het al. Monomer-coated very small superparamagnetic iron oxide particles as contrast medium for magnetic resonance imaging: preclinical in vivo characterization. Invest Radiol, 2002, 37 (4):167
Lawaczeck R, Bauer H, Frenzel Tet al. Magnetic iron oxide particles coated with carboxydextran for parenteral administration and liver contrasting. Acta Radiol, 1997, 38(4 Pt 1):584
Lacava Z G M, Azevedo R B, Martins E Vet al. Biological effects of magnetic fluids: toxicity studies. J Magn Magn Mater, 1999, 201:431
Author information
Authors and Affiliations
Additional information
XIA Zefeng, male, born in 1977, Doctor in Charge
This project was supported by a grant from the “863” Hitech Research and Development Program of China (No. 2001AA218051).
Rights and permissions
About this article
Cite this article
Zefeng, X., Guobin, W., Kaixiong, T. et al. Preparation and acute toxicology of nano-magnetic ferrofluid. Current Medical Science 25, 59–61 (2005). https://doi.org/10.1007/BF02831388
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF02831388